Feasibility of two dose - dense FEC regimens with growth factor support for adjuvant therapy in patients with <font color="blue">early_1</font> <font color="blue">breast_1</font> <font color="blue">cancer_1</font> <font color="blue">:_1</font> results from a randomised study of the Central European Cooperative Oncology Group ( CECOG ) . 
<br>
<br> Addition of epirubicin to adjuvant chemotherapy can provide <font color="blue">important_1</font> <font color="blue">benefits_1</font> for patients with early breast cancer , but the optimal dose remains unclear . Further improvements can be achieved with <font color="blue">dose_1</font> <font color="blue">-_1</font> <font color="blue">dense_1</font> <font color="blue">regimens_1</font> <font color="blue">,_1</font> <font color="blue">but_1</font> <font color="blue">densification_1</font> <font color="blue">of_1</font> <font color="blue">fluorouracil_1</font> <font color="blue">/_1</font> <font color="blue">epirubicin_1</font> <font color="blue">/_1</font> <font color="blue">cyclophosphamide_1</font> <font color="blue">(_1</font> <font color="blue">FEC_1</font> <font color="blue">)_1</font> <font color="blue">has_1</font> <font color="blue">proved_1</font> <font color="blue">difficult_1</font> <font color="blue">,_1</font> with FEC(60 ) providing little benefit over standard chemotherapy and FEC(100 ) associated with <font color="blue">toxicity_1</font> <font color="blue">._1</font> We investigated the feasibility of two intermediate dose - dense FEC regimens . Patients were randomised to six cycles of FEC(75 ) or FEC(90 ) , with all three drugs given on day 1 of each 14-day cycle . Patients also received pegfilgrastim 6 mg as a single subcutaneous injection on day 2 of each cycle . The primary efficacy endpoint was the <font color="blue">proportion_2</font> <font color="blue">of_2</font> <font color="blue">subjects_2</font> <font color="blue">receiving_2</font> <font color="blue">>_1</font> <font color="blue">or_1</font> <font color="blue">=_1</font> <font color="blue">85%_1</font> <font color="blue">relative_1</font> <font color="blue">dose_1</font> <font color="blue">intensity_1</font> and was achieved by 96% and 88% of patients in the FEC(75 ) and FEC(90 ) arms , respectively . Of 147 FEC(75 ) infusions , 4.1% <font color="blue">were_1</font> <font color="blue">delayed_1</font> <font color="blue">,_1</font> while 9.8% of 143 FEC(90 ) infusions <font color="blue">were_1</font> <font color="blue">delayed_1</font> <font color="blue">._1</font> The most common reasons for <font color="blue">delay_1</font> were <font color="blue">adverse_3</font> <font color="blue">events_3</font> <font color="blue">and_2</font> <font color="blue">personal_3</font> <font color="blue">/_3</font> <font color="blue">logistical_3</font> <font color="blue">reasons_3</font> <font color="blue">._3</font> One dose reduction occurred during the study ( FEC(90 ) ) , related to <font color="blue">diarrhoea_2</font> <font color="blue">._2</font> <font color="blue">Grade_3</font> <font color="blue">3_3</font> <font color="blue">-_3</font> <font color="blue">4_3</font> <font color="blue">haematological_4</font> <font color="blue">toxicities_4</font> were reported in two patients in the FEC(90 ) arm . There were no incidences of <font color="blue">febrile_4</font> <font color="blue">neutropenia_4</font> during the study . The most common adverse events were <font color="blue">increases_2</font> <font color="blue">in_2</font> <font color="blue">liver_5</font> <font color="blue">enzymes_5</font> <font color="blue">and_3</font> <font color="blue">gastrointestinal_5</font> <font color="blue">events_5</font> <font color="blue">;_5</font> no event resulted in discontinuation . Only one patient ( FEC(90 ) ) experienced <font color="blue">serious_1</font> <font color="blue">adverse_2</font> <font color="blue">events_2</font> <font color="blue">(_2</font> <font color="blue">vomiting_5</font> <font color="blue">and_5</font> <font color="blue">throat_5</font> <font color="blue">oedema_5</font> <font color="blue">)_5</font> <font color="blue">._2</font> In conclusion , dose - dense FEC(75 ) and FEC(90 ) are feasible with pegfilgrastim support . These regimens are associated with a very low risk of <font color="blue">Grade_3</font> <font color="blue">3_3</font> <font color="blue">-_3</font> <font color="blue">4_3</font> <font color="blue">toxicity_4</font> <font color="blue">._4</font>